American College of Chest Physicians includes ticagrelor in Antithrombotic Therapy and Prevention of Thrombosis guidelines

901

The American College of Chest Physicians (ACCP) has updated its guidelines on Antithrombotic Therapy and Prevention of Thrombosis to include a recommendation on the use of the oral antiplatelet medicine ticagrelor (Brilinta, AstraZeneca) tablets with low-dose aspirin to acute coronary syndrome patients. 

According to AstraZeneca, with the addition of these new ACCP guidelines, ticagrelor is now included in seven sets of cardiovascular treatment guidelines across the world: two sets in the EU, four in the USA and one in Canada.


“Brilinta is currently approved in 65 countries, reimbursed in 21 countries, and with the addition of the ACCP guidelines, is now included in seven sets of cardiovascular treatment guidelines,” said Simon Clowes, Global Product vice president, Brilinta. “These collective milestones provide an important foundation as we continue to work with authorities and decision-makers around the world to bring Brilinta to acute coronary syndrome patients.”


 

Specifically, the ACCP guidelines state:

 

For patients in the first year after an acute coronary syndrome who have not undergone percutaneous coronary intervention:

  • We recommend dual antiplatelet therapy (ticagrelor 90mg twice daily plus low-dose aspirin 75–100 mg daily or clopidogrel 75mg daily plus low-dose aspirin 75–100mg daily) over single antiplatelet therapy (Grade 1B).
  • We suggest ticagrelor plus low-dose aspirin over clopidogrel plus low-dose aspirin (Grade 2B).

 

For patients in the first year after an acute coronary syndrome who have undergone percutaneous coronary intervention with stent placement:

  • We recommend dual antiplatelet therapy (ticagrelor 90mg twice daily plus low-dose aspirin 75–100 mg daily, clopidogrel 75mg daily plus low-dose aspirin, or prasugrel 10mg daily plus low-dose aspirin over single antiplatelet therapy) (Grade 1B).
  • We suggest ticagrelor 90mg twice daily plus low-dose aspirin over clopidogrel 75mg daily plus low-dose aspirin (Grade 2B).

 

The revised guidelines are available online at http://chestjournal.chestpubs.org and are published in the February 2012 issue of CHEST.